GeneralNeutralBlockonomi · 4h ago5/10
📰
Incyte (INCY) Stock Dips Despite Japan’s Green Light for Minjuvi in DLBCL Treatment
Incyte's stock declined 0.78% to $98.22 despite receiving regulatory approval from Japan for Minjuvi to treat relapsed diffuse large B-cell lymphoma (DLBCL), marking the drug's second indication approval in the country. The counterintuitive market reaction suggests investors may have already priced in the approval or have concerns about commercial prospects.